Plain-English translation of NCT06831968 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are developing and testing a blood test called the Enlighten Device that may be able to predict whether a pregnant woman will develop postpartum depression after delivery. This is an observational study where pregnant women will provide a blood sample during their third trimester, and researchers will follow them after birth to see if the test accurately identifies who develops postpartum depression. The blood test is still experimental and not yet approved by the FDA.
Postpartum depression affects many women after childbirth, but doctors currently have no reliable way to predict who will develop it. If this blood test works, it could help identify at-risk women early so they can receive support and treatment before symptoms develop.
You likely qualify if…
You likely don't qualify if…
You will come to the clinic during your third trimester (around 27–30 weeks of pregnancy) for a single blood draw for the test. After delivery, you will be interviewed at 2 weeks postpartum and followed for up to 6 months to track your health and mood. You will not receive the results of the blood test during the study.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States
University of Virginia
Enrollment target
~500 participants
Started
March 2025
Primary completion
November 2026
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Meeta Pangtey, MPH
University of Virginia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.